Key Highlights

  • Hinge Health's third-quarter 2026 Revenue climbed 52% to $235.0 million.
  • Tempus AI booked $411.5 million of revenue, a 23.1% increase (calculated), but still reported a $14.9 million net loss.
  • Waystar's revenue reached $325.6 million, rising 21%, and its adjusted EBITDA totaled $139 million.
  • HealthStream lifted its 2026 revenue guidance to a range of $331.0 million to $333.0 million.
  • Tactile Systems Technology increased its 2026 adjusted EBITDA guidance to $50 million to $52 million.

Five Healthcare Services and Health Tech Names Report, Growing 7.1% to 52%

Third-quarter results for five healthcare services and health technology firms cover the period ending Sep 30, 2026, and their top-line gains fell between 7.1% and 52%. Four of the group published on Nov 2, 2026, while Tactile Systems Technology's update came through a Nov 3, 2026 call.

Hinge Health (NYSE:HNGE) generated $235.0 million of revenue, a 52% rise, along with $57.4 million of GAAP net income. Tempus AI (NASDAQ:TEM) produced $411.5 million, a 23.1% gain on a calculated basis, but carried a $14.9 million net loss. Waystar (NASDAQ:WAY) earned $325.6 million in revenue, up 21%, plus $31.0 million of net income.

HealthStream (NASDAQ:HSTM) recorded $83.3 million of revenue, up 8.9%, and $5.4 million of net income. Tactile Systems Technology (NASDAQ:TCMD) brought in $91.9 million, up 7.1%, and $7.2 million of net income. Four of the five companies were profitable, though the bases differ, and Tempus AI's loss narrowed partly because of unrealized Equity gains.

Hinge Health: Billings Outperformance and a Raised Full-Year Target Behind the Surge

Hinge Health's sales reached $235.0 million from $154.2 million a year before, clearing its own $223 million to $225 million forecast range. Leadership credited the excess entirely to billings, pushed higher by stronger yield, which refers to the portion of eligible members who enroll and keep engaging.

Swinging from a $1.8 million net loss in the earlier period, the company posted GAAP Net Income of $57.4 million, which equals $0.66 a share. Non-GAAP Operating Margin widened to 33% from 20%, and free Cash Flow reached $112.7 million.

Full-year 2026 revenue guidance now stands at $879 million to $881 million, up from $856 million to $860 million. The president is leaving the role on Jan 1, 2027 and will take a board seat on Jan 4, 2027. An integrated gastrointestinal program is aimed at summer 2027, with meaningful sales anticipated in 2028.

Tempus AI: Equity Gains and a Shrinking Operating Loss Explain the Narrower Deficit

Tempus AI's revenue grew to $411.5 million from $334.2 million, with diagnostics contributing $303.5 million and data and applications adding $108.1 million. The net Deficit shrank to $14.9 million, or $0.08 a share, from $80.0 million.

Per the filing, other income moved mostly because unrealized gains on marketable equity holdings rose by $44.0 million, so the narrowing is not entirely operational. Adjusted EBITDA went from $1.5 million to $25.6 million.

Leadership pointed to data licensing contracts that should Yield $193 million across five years, and it agreed in July to take over a molecular diagnostics Business at a $1.5 billion enterprise value. The target's Shareholder meeting is slated for Nov 30, and closing is expected in the fourth quarter. Because the transcript was garbled, the raised 2026 revenue range cannot be read reliably, so it is left out of this piece.

Waystar: Reported Growth of 21% Versus Organic Growth of 10%

Waystar's Top Line grew 21% to $325.6 million, but excluding acquisitions the increase was 10%. Subscription sales jumped 34% to $181 million (12% organically), and volume-linked sales went up 8% to $143 million. Patient payment income rose a modest 5%, reflecting providers moving away from printed statements.

Adjusted EBITDA expanded 24% to $139 million, equal to a 43% margin, and unlevered free cash flow totaled $115 million. The company reported net Leverage of 2.2 times.

Adjusted EBITDA guidance was lifted to a range of $543 million to $549 million. The revenue forecast of $1.277 billion to $1.287 billion suggests fourth-quarter growth near 6%, a pace that management says three factors reduce by roughly 4 points. The files do not state prior revenue guidance.

HealthStream: Rising Guidance Coexists With Lower Net Income

HealthStream's sales rose 8.9% to $83.3 million; deals closed in late 2025's final quarter contributed $3.2 million of the gain. Earnings slid 11.7% to $5.4 million, which works out to $0.18 a share, as spending moved up to $76.7 million from $68.9 million. A Cybersecurity event disclosed Jul 29, 2026 cost about $250,000 during the period.

The adjusted EBITDA line improved by 1.0%, reaching $19.3 million. Forecasts moved higher on both fronts: revenue is now projected between $331.0 million and $333.0 million, replacing a $327.0 million to $332.0 million band, while adjusted EBITDA is seen at $77.0 million to $78.0 million.

On Sep 14, 2026, a private Placement brought in roughly $40.0 million; afterward, cash plus marketable holdings totaled $115.2 million. The board approved a $0.035 quarterly dividend, which is payable Nov 27, 2026.

Tactile Systems Technology: Lymphedema Gains Offset Airway Clearance Weakness

Tactile Systems Technology's sales came to $91.9 million, reflecting a 7.1% increase. Lymphedema generated $81.8 million after a 13.1% expansion, whereas airway clearance receipts sank 25.1% to $10.0 million; some durable medical equipment buyers were working off surplus inventory amid a product transition.

Tactile's Bottom Line landed at $7.2 million, equal to $0.31 a share, against $8.2 million earlier. Gross margin moved up to 76.7% from 75.8%, but operating outlays grew 12.7% to $60.9 million. Adjusted EBITDA came in at $14.3 million.

The 2026 revenue guidance remained at $360 million to $366 million, while adjusted EBITDA guidance was increased to $50 million to $52 million. Full-year airway clearance revenue is now expected to decline by a mid-to-high single-digit percentage. A Flexitouch Pro submission aims for a launch in the second half of 2027, pending regulatory clearance.

Health Tech Growth Spread: Scale, Profit and Margin Differences Across Five Names

Growth stretches between 7.1% at Tactile Systems Technology and 52% at Hinge Health, a 44.9-point spread (calculated). Averaging the five growth rates gives roughly 22.4% (calculated), but that mean treats the smallest and biggest companies as equals.

Pooled revenue approximates $1.15 billion (calculated), and Tempus AI accounts for about 36% of it (calculated). Pooled net income is about $86.1 million (calculated), which subtracts Tempus AI's $14.9 million loss from four profits.

The bases are not uniform: Hinge Health and Waystar rely on non-GAAP measures that strip out certain items, and Tempus AI's loss is shaped by equity gains. Waystar's 21% includes acquired revenue, against an organic rate of 10%.

What to Watch Next: Tempus Deal Vote, Hinge Leadership Handover and Upcoming Payouts

The target of Tempus AI's planned purchase holds a shareholder meeting on Nov 30, and completion is anticipated during the fourth quarter. HealthStream's Dividend pays on Nov 27, 2026 for holders recorded on Nov 16, 2026.

On Jan 1, 2027, Hinge Health's president steps aside; that person joins the board on Jan 4, 2027. Tactile's billing code request reaches final review in February 2027, while the Flexitouch Pro targets the second half of 2027.

Waystar intends to add context alongside its formal outlook next quarter, though its materials identified no dated event.